TriSalus Life Sciences, Inc. (TLSI)

Market Cap	167.71M
Revenue (ttm)	29.43M
Net Income (ttm)	-33.25M
Shares Out	30.49M
EPS (ttm)	-1.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,483
Open	5.33
Previous Close	5.58
Day's Range	5.32 - 5.63
52-Week Range	3.50 - 10.42
Beta	0.48
Analysts	Strong Buy
Price Target	11.75 (+113.64%)
Earnings Date	Mar 27, 2025

About TLSI

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced panc...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2010
• Employees: 112
• Stock Exchange: NASDAQ
• Ticker Symbol: TLSI
• Website: https://trisaluslifesci.com

Financial Performance

In 2024, TriSalus Life Sciences's revenue was $29.43 million, an increase of 58.99% compared to the previous year's $18.51 million. Losses were -$33.25 million, -47.46% less than in 2023.

Analyst Forecast

According to 6 analysts, the average rating for TLSI stock is "Strong Buy." The 12-month stock price forecast is $11.75, which is an increase of 113.64% from the latest price.

Price Target

$11.75

(113.64% upside)

Analyst Consensus: Strong Buy